Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interruption on patients, underscoring the need for continued treatment to prevent disease progressionFurther poster presentations examine early real-world experience with Rezdiffra and the clinical burden of MASH CONSHOHOCKEN, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Madr ...

核心人物背景 - 核心人物拥有斯坦福大学有机合成博士学位（2009年）[1] - 核心人物曾任职于大型制药公司默克（2009-2013年）[1] - 核心人物在生物技术领域有从业经验，包括初创公司Theravance/Aspira，之后受雇于加州理工学院[1] - 核心人物是1200 Pharma公司的首位员工和联合创始人，该公司从加州理工学院分拆并获得八位数重大投资[1] - 核心人物目前仍是一名活跃的投资者，专注于市场趋势，尤其是生物技术股票[1] 分析师持仓披露 - 分析师通过股票、期权或其他衍生品对MDGL持有有益的长期头寸[2] - 分析师在第三季度财报后继续持有MDGL，并且同时做多LLY[3]

CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financi ...

Pharma companies are betting big on drugs that treat MASH, a serious liver disease linked to obesity and metabolic issues. Several companies have snapped up experimental drugs this year, including Roach and Novon Nordisk, which uh each have agreed to acquire liver disease focused companies and deals potentially worth several billion dollars a piece. The moves follow successful launch of Magical's drug res, which was the first match drug cleared by the FDA back in March 2024.For more in the increasingly comp ...

CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2025 to 27 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasd ...

并购市场整体趋势 - 2025年并购活动回暖，交易价值同比增长29%，交易数量增长8% [3] - 高盛预测2026年新交易数量将再增长15% [3] - 潜在并购目标股票组合自9月初以来表现超越标普1500指数7个百分点 [2] 重大并购案例 - 电子艺界将被投资者财团私有化，成为史上最大杠杆收购，消息公布后股价两日内飙升超过20% [1] 重点并购目标公司 - Insmed：医疗保健行业，市值288亿美元，年初至今总回报率96% [5] - Madrigal Pharmaceuticals：医疗保健行业，市值95亿美元，年初至今总回报率8% [5] - Krystal Biotech：医疗保健行业，市值88亿美元，年初至今总回报率3% [6] - Mineralys Therapeutics：医疗保健行业，市值49亿美元，年初至今总回报率213% [7] - TripAdvisor：通信服务行业，市值49亿美元，年初至今总回报率15% [8] - Vera Therapeutics：医疗保健行业，市值48亿美元 [9]

公司比特币储备增持 - 公司以平均价格113,314美元（157,428加元）收购了31.36个比特币，将其添加到比特币储备中[1] - 公司目前比特币储备总量达到42.36个BTC，平均购买价格为110,087美元（152,504加元）[1] 公司未来资金使用计划 - 公司计划在未来几周内，将近期宣布的私募融资第一轮的大部分收益用于购买更多比特币[2] 公司业务概览 - 公司是一家非托管的比特币业务，其使命是赋能独立性，通过使比特币对日常用户有用，为用户提供现代银行业的便利和比特币的优势[3] - 公司将此使命视为货币的未来证明，其现有的比特币ATM和在线比特币门户业务部门产生现金流以帮助资助这一使命[3]

Madrigal Pharmaceuticals (NASDAQ: MDGL ) has quickly become a major player in metabolic liver disease treatments with Rezdiffra (resmetirom), which is indicated for F2-F3 MASH. This drug was authorized under accelerated approval in the US and is already showing blockbuster potential. This is despite havingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohi ...

Madrigal Pharmaceuticals (NASDAQ: MDGL ) has quickly become a major player in metabolic liver disease treatments with Rezdiffra (resmetirom), which is indicated for F2-F3 MASH. This drug was authorized under accelerated approval in the US and is already showing blockbuster potential. This is despite havingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohi ...

PresentationUnknown Analyst Good morning, everyone. Very excited to be kicking off the Morgan Stanley Healthcare Conference with the Madrigal team this morning. Thank you guys for joining me. I'm joined by CEO, Bill Sibold; CFO, Mardi Dier; and CMO, Dave Soergel. So thank you guys for joining us early on a Monday. We're very excited to be starting this conference in this way. Before I dive in, I'm going to read a brief disclaimer. For important disclosures, please see the Morgan Stanley research disclosure ...